Summary
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis: a Cochrane review
Xiaoqin Wang11, Yanfang Ma2, Xu Hui3,4, Meixuan Li3,4, Jing Li3,4, Jinhui Tian3,4, Qi Wang5, Peijing Yan6, Jianfeng Li7, Ping Xie7, Kehu Yang3,4, Liang Yao5
Affiliation of the authors
1Michael G DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Canada. 2School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region, China. 3Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. 4Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China. 5Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada. 6Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. 7Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China.
DOI
Quote
Wang X, Ma Y, Hui X, Li M, Li J, Tian J, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis: a Cochrane review. Emergencias. 2025;37:384-6